Cargando…

Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report

BACKGROUND: Nivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy. Up-to-now, few data are available concerning brain activity of this treatment and con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pluchart, Hélène, Pinsolle, Julian, Cohen, Julien, Ferretti, Gilbert R., Bedouch, Pierrick, Giaj Levra, Matteo, Toffart, Anne-Claire, Moro-Sibilot, Denis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499003/ https://www.ncbi.nlm.nih.gov/pubmed/28679408 http://dx.doi.org/10.1186/s13256-017-1334-z

Ejemplares similares

Impact of polypharmacy and comorbidity on survival and systemic parenteral treatment administration in a cohort of hospitalized lung-cancer patients
por: Pluchart, Hélène, et al.
Publicado: (2023)

Comparison of seven comorbidity scores on four-month survival of lung cancer patients
por: Pluchart, Hélène, et al.
Publicado: (2023)

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2017)

Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer
por: Pierret, Thomas, et al.
Publicado: (2020)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer
por: Gobbini, Elisa, et al.
Publicado: (2020)

Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine
por: Pinsolle, Julian, et al.
Publicado: (2019)

Factors associated with survival of patients with solid Cancer alive after intensive care unit discharge between 2005 and 2013
por: Gheerbrant, Hubert, et al.
Publicado: (2021)

Epidemiology of oligometastatic non-small cell lung cancer: results from a systematic review and pooled analysis
por: Gobbini, Elisa, et al.
Publicado: (2021)

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2014)

Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic
por: Veron, Marie, et al.
Publicado: (2023)

Quels malades peuvent et doivent aller en réanimation ?: Which patients can and should go to intensive care?
por: Toffart, A.-C., et al.
Publicado: (2021)

Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
por: Assié, Jean-Baptiste, et al.
Publicado: (2020)

Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab
por: Chouaïd, Christos, et al.
Publicado: (2022)

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study
por: Toffart, Anne-Claire, et al.
Publicado: (2014)

Clinical evaluation of pharmacists’ interventions on multidisciplinary lung transplant outpatients’ management: results of a 7-year observational study
por: Duwez, Marion, et al.
Publicado: (2020)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab
por: Pham, Félix, et al.
Publicado: (2022)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Stereotaktische Radiotherapie plus Nivolumab bei NSCLC
por: Krug, David, et al.
Publicado: (2023)

Altered splicing of ATG16‐L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non‐small cell lung cancer
por: Hatat, Anne‐Sophie, et al.
Publicado: (2022)

Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?
por: Nicosia, Luca, et al.
Publicado: (2020)

COVID-19 mass vaccination – an illustration of the impact of syringe choice on the effectiveness of mass vaccination campaigns
por: Mazet, Roseline, et al.
Publicado: (2022)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Efficacy of Plasmapheresis in Nivolumab-Associated ANCA Glomerulonephritis: A Case Report and Pathophysiology Discussion
por: Laamech, Reda, et al.
Publicado: (2021)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yi, et al.
Publicado: (2020)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

Corticosteroids vs. corticosteroids plus cycloporin A in adult minimal changes disease
por: Goumenos, Dimitrios S, et al.
Publicado: (2009)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature
por: Matsuo, Keisuke, et al.
Publicado: (2019)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Epidemiology and Clinical Burden of Meningococcal Disease in France: Scoping Review
por: Baloche, Alexiane, et al.
Publicado: (2023)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
por: Salaün, Hélène, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c076o0meemm2e4trddrrg9j1c7